论文部分内容阅读
目的分析胃癌患者联合检验肿瘤标志物的结果和价值。方法选取2015-01-2015-12郑州大学第二附属医院50例胃癌患者作为试验组,良性胃病患者50例作为对照组A,体检健康人员50例作为对照组B。采集静脉血液检验CEA、CA199、CA242、CA724水平,观察比较检验结果。结果对照组A、B之间的检测结果差异不明显,P>0.05。试验组各项检测结果均高于对照组;胃癌Ⅲ-Ⅳ期各项指标阳性检出率均高于Ⅰ~Ⅱ期患者,差异有统计学意义,P<0.05。结论胃癌患者的血清CEA、CA199、CA242、CA724水平明显升高,联合检验肿瘤标志物能够提高诊断准确性,为临床治疗提供科学依据。
Objective To analyze the results and value of combined detection of tumor markers in patients with gastric cancer. Methods Fifty patients with gastric cancer from the Second Affiliated Hospital of Zhengzhou University from January 2015 to December 2015 were selected as the experimental group, 50 patients with benign gastric diseases as control group A, and 50 healthy subjects as control group. Venous blood was collected to test the levels of CEA, CA199, CA242 and CA724, and the test results were compared. Results There was no significant difference between the control group A and B (P> 0.05). The test results in the experimental group were higher than those in the control group. The positive rates of all the indicators in stage Ⅲ-Ⅳ of gastric cancer were higher than those in stage Ⅰ ~ Ⅱ, the difference was statistically significant (P <0.05). Conclusion Serum levels of CEA, CA199, CA242 and CA724 in patients with gastric cancer are significantly higher. Combined testing of tumor markers can improve the diagnostic accuracy and provide a scientific basis for clinical treatment.